SOL-R enrollment complete; shareholders approve 8.75M share increase and CEO award

OCULAR THERAPEUTIX, INC

SOL-R Phase 3 trial for AXPAXLI (wet AMD) completed enrollment on May 31, 2025; target randomization of at least 555 subjects.
Stockholders approved Amendment No. 4 increasing 2021 Stock Incentive Plan shares by 8,750,000 shares.
Stockholders approved Amended and Restated ESPP increasing shares by 2,000,000 and removing evergreen provision.
CEO Dr. Dugel granted performance stock option award for up to 2,750,000 shares at $7.44/share, vesting on stock price hurdles.
Certificate of Amendment filed to provide officer exculpation (limitation of liability) per Delaware law.

item 5.02item 5.03item 5.07item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.